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Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses 
 
 
 
10% of cases of arthritis 
that begin in childhood. The disease is unique in terms of clinical manifestations, severity of 
joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show 
that serum from SoJIA patients induces the transcription of innate immunity genes, including 
interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, 
SoJIA PBMCs release large amounts of IL-1
 
 
 
. We administered recombinant IL-1 receptor 
antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission 
was obtained in seven out of nine patients and a partial response was obtained in the other 
two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that 
underlies SoJIA and that this cytokine represents a target for therapy in this disease.
 
Juvenile idiopathic arthritis (JIA), which affects
an estimated 250,000 children in the United
States alone, is an important cause of short- and
long-term disability. The term JIA encompasses a
heterogeneous group of diseases that is classified
according to three major types of presentation:
(a) oligoarthritis, (b) polyarthritis, and (c) systemic
onset JIA (SoJIA). Each of these groups has a
different prognosis and responds differently to
available therapies (1, 2); this suggests that their
pathogenesis also is unique.
Children who have SoJIA present with
systemic symptoms, fever, and/or rash, which
may precede the development of arthritis by
months or even years. Fever, anemia, leukocyto-
sis, and elevated erythrocyte sedimentation rate
(ESR) are the main initial features of the disease.
Because these symptoms are nonspecific, patients
often undergo extensive diagnostic tests and
hospitalizations. Although the disease outcome
is highly variable, the overall prognosis seems
to correlate with the persistence of systemic
symptoms and the number of joints that is in-
volved 6 mo into the disease course (3–6).
Overall, up to 50% of SoJIA patients continue
to have active arthritis 5–10 yr after diagnosis
(2, 7, 8). Because long-term disability is corre-
lated directly with duration of active disease,
this group has the most severe outcome, and
thus, represents the most serious challenge to
pediatric rheumatologists. The pathogenesis of
SoJIA remains an enigma, but increased levels
of IL-6 seem to correlate with the systemic activ-
ity of the disease and with the development of
arthritis (9).
Multi-drug treatment of SoJIA patients de-
pends on the phase (systemic versus arthritic) of
the disease and the extent of involvement. Al-
though a minority of patients do well with
nonsteroidal anti-inflammatory drugs, most pa-
tients require oral and/or systemic corticosteroids
(10) and methotrexate (MTX) for prolonged
periods to treat the systemic manifestations and
arthritis, respectively. Steroid treatment results
in significant morbidity, including vertebral
compression fractures, cataracts, and severe
growth retardation. Other medications that are
used in recalcitrant cases include intravenous
gamma globulin, cyclosporine, and thalidomide
(11, 12). Anti-TNF therapy is effective against
some types of JIA (13, 14), but most SoJIA pa-
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Figure 1. (a) Effects of SoJIA sera on healthy PBMCs. Incubation 
of healthy PBMCs with autologous sera and sera from four patients who 
had active SoJIA (SYS33, SYS46, SYS53, and SYS27) induced up-regula-
tion of 46 genes. The microarray data of healthy PBMCs that were 
incubated with patients’ sera were normalized to the same PBMCs that 
were cultured with autologous serum. Probes that did not differ signifi-
cantly between unincubated PBMCs and PBMCs that were cultured with 
autologous serum were selected. Of those, only gene probes whose 
expression was up-regulated more than twofold by at least two SoJIA 
sera were selected further. IL-6 did not fulfill this criterion but is shown 
for comparison. Median fold up-regulation by the four SoJIA sera 
incubation is depicted in the left column. Number of SoJIA sera that 
induced greater than twofold up-regulation is shown in the next column. 
(b) Expression of the gene probes selected in Fig. 1 a in the PBMCs of 16 
active SoJIA patients. The patient’s PBMCs expression data were normal-
ized to the median expression of the same gene probes in the PBMCs of 
12 healthy children. Median gene expression and number of samples 
with greater than twofold up-regulation are depicted in the first two 
columns. Third column represents the number of samples with a P 
(present) flag according to Affymetrix MAS 5.0 scaled gene expression 
data. Asterisks on the gene denominations mean that the expression 
of those genes is significantly different (Mann-Whitney   0.05) in 
patients compared with controls. p-values are given next to these genes. 
(c) Induction of IL-1b protein secretion in healthy PBMCs incubated with 
SoJIA sera. Supernatants from 6 h incubation of healthy PBMCs with 12 
SoJIA sera and 3 healthy controls were assayed for IL-1b production by 
Luminex. (d) Induction of IL-1b protein secretion in SoJIA patients who 
did and did not have systemic symptoms. IL-1b protein secretion is 
induced preferentially by sera from SoJIA patients who experience sys-
temic symptoms (SoJIA1, n   5) over those patients who only had active 
arthritis (SoJIA2, n   7). All results were analyzed using nonparametric 
tests (Mann-Whitney). 
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tients do not respond to this treatment (15, 16). Here we
show data which indicate that IL-1 is a major mediator of the
inflammatory cascade that underlies SoJIA, and that IL-1Ra is
an effective treatment for this disease.
 
RESULTS
Incubation of healthy PBMCs with SoJIA serum up-regulates 
transcription of innate immunity genes
 
We have previously shown that interferon-
 
 
 
, which is
present in the serum of patients who have systemic lupus
erythematosus (SLE), induces the differentiation of healthy
monocytes into dendritic cells (17) and that all active SLE
PBMCs display an interferon signature (18). After a similar
strategy, we cultured healthy PBMCs with the serum of four
active SoJIA patients and examined the induced gene tran-
scription pattern using Affymetrix oligonucleotide microar-
rays (accession nos. are provided in Table S1, available at
http://www.jem.org/cgi/content/full/jem.20050473/DC1).
Each PBMC sample was processed: (a) fresh without culture;
(2) after 6 h incubation with autologous serum; and (3) after
6 h incubation with SoJIA serum. Fig. 1 a shows 46 genes
whose expression increased more than twofold in healthy
PBMCs that were cultured with SoJIA serum. Up-regulated
genes included several members of the IL-1 cytokine/cyto-
kine receptor family. IL-1b transcription was induced by 4/4
SoJIA sera from 4- to 40-fold (median, 8.2-fold). IL-1a was
up-regulated by 3/4 of the SoJIA sera (median 13-fold), as
were their receptors, IL-1R1 and IL-1R2 (median four- and
twofold, respectively). In contrast, IL-6 was up-regulated by
only one of the SoJIA sera. RT-PCR analysis of IL-1b tran-
scription confirmed the microarray data (unpublished data).
SoJIA sera also induced the transcription of chemokines that
are involved in the chemotaxis of stem cells (CXCL2), neu-
trophils (CXCL1, CXCL3, CXCL5, CXCL6), monocyte/
macrophages (CCL2, CCL7), and lymphocyte/dendritic cells
(CCL20; reference 19). CCR1, a receptor for numerous che-
mokines which is considered to be a target in autoimmunity
(20), also was increased. Among receptors that are associated
with pathogen recognition, fibronectin was the most signifi-
cantly up-regulated (17-fold), followed by the diphtheria
toxin receptor (9.6-fold); and the lectins, ANGPTL4 and
MDL1/CLECSF5 (greater than fivefold). Pentraxin-3, the
scavenger macrophage receptor with collagenous structure
(MARCO), toll-like receptor 2, and the C1q receptor were
up-regulated two- to fourfold by 3/4 SoJIA sera. Triggering
receptor expressed on myeloid cells (TREM1) was up-regu-
lated significantly only by the sera from the two untreated pa-
tients. Transcripts which encode molecules that are involved
in cell adhesion and/or motility, as well as a variety of en-
zymes, including the proinflammatory cyclooxygenase-2,
were up-regulated. Other up-regulated molecules are listed
in Fig. 1 and Tables S1 and S2 (available at http://www.jem.
org/cgi/content/full/jem.20050473/DC1).
The remarkable transcription induction capacity of
SoJIA serum led us to consider that the observed genes also
may be up-regulated in SoJIA patients. Microarray analysis
showed that 
 
 
 
800 transcripts were overexpressed in the
PBMCs of 16 patients, compared with 12 healthy controls
(unpublished data). Of the 46 gene transcripts that were in-
duced by SoJIA sera, 30 were present in more than one third
of the SoJIA PBMCs; 17 were increased significantly in
SoJIA compared with control PBMCs (Mann-Whitney P 
 
 
 
0.05; Fig. 1 b and Tables S2 and S4, available at http://
www.jem.org/cgi/content/full/jem.20050473/DC1). These
included IL-1b and the IL-1 decoy receptor (IL-1R2),
CXCL1, and CCR1; this may explain the neutrophilia and
increased monocyte numbers in these patients. C1qR; toll-
like receptor 2; PTX3; and the proinflammatory enzyme,
prostaglandin G/H synthase-2/cyclooxygenase-2, also were
increased significantly. KCNJ15, an inward-rectifier–type
potassium channel that is linked to the lysosome-mediated
control of IL-1b secretion (21), was among the most signifi-
cantly up-regulated genes in PBMCs from SoJIA patients.
Conversely, a group of gene transcripts that was induced af-
ter 6 h of incubation of healthy PBMCs with SoJIA sera in
Figure 2. (a) Production of IL-1b by activated SoJIA PBMCs. PBMCs 
from SoJIA patients (n   5) and healthy controls (n   5) were activated 
with PMA/Ionomycin for 24 h. Release of IL-1b into the supernatants 
was assayed with Luminex. Production of IL-6 (b) and TNF (c) by the same 
activated SoJIA PBMCs. p-values were calculated by nonparametric 
(Mann-Whitney) tests. 
S
 
O
 
JIA IS AN IL-1–MEDIATED DISEASE | Pascual et al.
 
1482
 
vitro were not detected in SoJIA patients. These included
IL-1a, CCL2, CCL7, CCL20, fibronectin, SDC2, and oth-
ers (Fig. 1 b).
 
SoJIA sera induce healthy PBMCs to secrete IL-1b
 
The increased expression of IL-1b was analyzed further at
the protein level. SoJIA sera induced healthy PBMCs to
produce 63 
 
 
 
 39 pg/ml of IL-1b (mean 
 
 
 
 SD; range 
 
 
 
10–
136 pg/ml; 
 
n
 
 
 
 
 
 10; P 
 
 
 
 0.017), whereas healthy sera did
not (
 
 
 
10 pg/ml; 
 
n
 
 
 
 
 
 3; Fig. 1 c). Sera from febrile SoJIA
patients were more efficient at inducing IL-1b secretion than
were sera from afebrile patients (P 
 
 
 
 0.005), which, in turn,
were more efficient than healthy sera (P 
 
 
 
 0.003; Fig. 1 d).
Taken together, these data indicate that SoJIA serum induces
transcription and translation of IL-1b in healthy PBMCs.
 
Activated SoJIA PBMCs produce high levels of IL-1b
 
Recently, monocytes from patients who had autoinflamma-
tory diseases were shown to produce higher levels of IL-1b
than control monocytes (22). Thus, we tested the capacity of
SoJIA patients’ PBMCs to secrete IL-1b upon activation
with PMA-ionomycin. After 24 h, PBMCs from five SoJIA
patients secreted 333 
 
 
 
 204 pg/ml (range, 154–569 pg/ml),
whereas PBMCs from five healthy controls secreted 21 
 
 
 
 4
pg/ml IL-1b (mean 
 
 
 
 SD; P 
 
 
 
 0.007; Fig. 2 a). In the same
cultures, IL-6 and TNF production was not significantly dif-
ferent between patients and controls (Fig. 2 b).
 
Administration of IL-1Ra resolves SoJIA clinical symptoms
 
The above findings suggested that SoJIA patients might suffer
from a dysregulation of IL-1 production, as opposed to other
forms of chronic inflammatory arthritis (e.g., rheumatoid ar-
thritis) that depend on TNF. Therefore, we hypothesized that
SoJIA patients would benefit from therapy with an IL-1 an-
tagonist. Nine patients who had active disease that was resis-
tant to conventional aggressive treatment were treated with a
commercially available rIL-1Ra (Anakinra, Amgen Inc.). The
clinical characteristics of the patients at treatment initiation are
summarized in Table I. Seven of nine patients had systemic
symptoms and eight had active, uninterrupted arthritis that
had lasted for 5–125 mo. All patients were receiving oral
prednisone, 7/9 were on i.v. methylprednisolone, 7/9 were
on MTX, and 4/9 had received anti-TNF (infliximab) ther-
apy for 12–25 mo without improvement. rIL-1Ra was initi-
ated as a daily subcutaneous injection at 2 mg/kg, up to 100
mg. Patients were followed every 2 mo with a complete phys-
ical examination and laboratory tests for an average of 6.6 mo
(range 2–12 mo) after therapy initiation. All nine patients re-
sponded to therapy. All patients who experienced systemic
symptoms (7/9) became afebrile within the first week after
initiation of therapy, and remained afebrile for the follow-up
period of 2–12 mo (Fig. 3 a). Arthritis score completely re-
solved in 6/8 patients who had active arthritis at the time of
therapy initiation, and it improved in the remaining two
patients (Sys2 and Sys15) who had had a persistent course
without remissions for 12 and 3 yr, respectively. i.v. methyl-
prednisolone was discontinued during the herein described fol-
low-up period in 5/7 patients who had been on this therapy
for months. This medication was tapered and eventually was
discontinued in the remaining two patients. Oral prednisone
was stopped in one patient and tapered in 6/7 patients (Fig. 4).
Although the patient who had the longest unremitting disease
showed persistent response of her systemic symptoms, her ar-
thritis responded only initially; she had two active joints at the
4-mo follow-up (Fig. 3 b). Complications included two epi-
sodes of hypotension and vomiting with negative viral and
bacterial cultures in one patient who had underlying myocar-
dial dysfunction. Therapy was restarted after resolution of the
symptoms without complications. All patients experienced
mild erythema at the local injection sites. The core set criteria
for the time Anakima treatment was started and the last follow-
up are summarized in Tables S7–S15 (http://www.jem.org/
cgi/content/full/jem.20050473/DC1).
 
Administration of IL-1Ra normalizes SoJIA 
laboratory findings
 
The striking improvement in clinical symptoms upon IL-
1Ra treatment was associated with a parallel improvement in
the inflammatory markers. Leukocytosis resolved in 9/9 pa-
tients (Fig. 3 c). The chronic persistent anemia improved in
 
Table I.
 
Clinical characteristics of the patients at the time of initiation of anakinra therapy
 
Patient Age Sex
Disease
duration
Flare
duration
Fever/
rash
Active
arthritis
Oral
prednisone
i.v.
solumedrol MTX
Previous
anti-TNF Follow-up
 
mo mo (frequency) mo
 
Sys33 17 F 36  6  Yes Yes Yes Yes (q. 4 wk) Yes Yes 12 
Sys47 9 M 29  12  Yes Yes Yes Yes (q. 2 wk)  No No 12 
Sys56 4 F 23  13  Yes Yes Yes Yes (q. 1 wk) Yes No 8 
Sys2 12 F 125  125  Yes Yes Yes Yes (q. 4 wk) Yes Yes 6 
Sys12 6 F 35  10  Yes No Yes Yes (q. 4 wk) Yes Yes 6 
Sys15 4 F 30  30  No Yes Yes Yes (q. 4 wk) No Yes 6
Sys21 6 F 40  5  Yes Yes Yes Yes (q. 2 wk) Yes No 4 
Sys38 4 M 38 18  Yes Yes Yes No Yes No 4 
Sys25 14 F 144 30 No Yes Yes No Yes No 2 
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all but one patient. This was demonstrated by an increase of
hemoglobin levels (Fig. 3 d) and erythrocyte counts (not de-
picted). Thrombocytosis resolved in 9/9 patients. Only one
patient (Sys2) showed a rebound increase at the 4–6 mo fol-
low-up (Fig. 3 e). Most significant (P 
 
 
 
 0.0002) was the re-
duction of ESR, with 8/9 patients reaching a normal value
within 2 mo. One patient (Sys58) who had a slower resolu-
tion of arthritis symptoms required a longer time (8 mo) to
normalize the ESR. Two patients (Sys2 and Sys12) had a
mild rebound in ESR at the 4-mo visit; this coincided with
temporary withdrawal of rIL-1Ra for viral-like symptoms
(Fig. 3 f). Thus, treatment of SoJIA patients with daily rIL-
1Ra results in prompt clinical and biologic improvement.
 
DISCUSSION
 
Three sets of findings lead us to conclude that dysregulated
production of IL-1 plays a critical role in the pathogenesis of
SoJIA. First, the serum of SoJIA patients up-regulates the ex-
pression of IL-1a, IL-1b, and other innate immunity genes
by healthy PBMCs. Second, the patient’s PBMCs produce
an excess of IL-1b upon activation. Third, treatment with
IL-1Ra efficiently treats the disease.
Although SoJIA serum induces IL-1b secretion by
healthy PBMCs in vitro, IL-1b serum levels in our patients
were as low as those of healthy individuals. Serum cytokine
levels, however, may not reflect a cytokine’s role in disease
pathogenesis. For example, virtually all PBMCs from chil-
Figure 3. Values of (a) temperature; (b) active joint count; (c) 
white blood cells (WBC); (d) hemoglobin; (e) platelet count; and (f) 
ESR in 9 SoJIA patients. Values on the x axis represent months before 
( 2) initiation of Anakinra treatment (0) and up to 2–12 mo of follow up 
(average, 6.6 mo). Arrows indicate the time of treatment initiation. p-val-
ues were calculated at time 0 and at 2-mo follow-up (paired, two-tailed t 
test). Color codes for individual patients (from Table I) are represented at 
the bottom. 
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dren who have SLE display an interferon-
 
 
 
 signature, al-
though this cytokine is detectable in the serum in less than
50% of patients (18). Furthermore, IL-1b is involved in the
pathogenesis of familial autoinflammatory syndromes (22,
23), and blocking IL-1 with IL-1Ra resolves the clinical
symptoms that are associated with mutations in the NALP3/
cryopyrin gene (Muckle-Wells syndrome and neonatal onset
multisystem inflammatory disease/chronic, infantile, neu-
rologic, cutaneous and articular syndrome) (24). However,
the serum IL-1 concentration and the cytokine mRNA in
PBMCs from these patients are not raised either (25). Al-
though SoJIA normally is a sporadic disease, de novo muta-
tions and/or subtle polymorphisms of genes within the IL-1
pathway could contribute to its pathogenesis. The IL-1 fam-
ily includes nine members (26), eight of which were not up-
regulated using real-time PCR in patients’ PBMCs (unpub-
lished data).
The central role of IL-1 in SoJIA is illustrated by the re-
markable clinical response of the patients to IL-1Ra. Nine
out of nine patients who had long-standing disease that was
resistant to other forms of treatment responded to this ther-
apy. Seven of nine cleared symptoms and laboratory abnor-
malities within days to weeks of therapy initiation; one pa-
tient showed a clear trend toward improvement. One patient
who had had active disease for 12 uninterrupted years had a
quick response and remained afebrile for the 6-mo follow-up
period. Her arthritis and laboratory abnormalities, however,
improved only transiently. Microarray analysis showed that
this patient had a modest (2.7-fold) up-regulation of the IL-
1b gene (Table S2). Complete characterization of her IL-1b
response to PBMC activation is underway.
IL-1b was shown to be a key mediator of synovial inflam-
mation in experimental arthritis models. IL-1b–deficient mice
fail to develop chronic, erosive arthritis in response to arthri-
togenic stimuli (27) and IL-1Ra–deficient mice develop au-
toimmunity and arthritis spontaneously (28). IL-1 blockade
with recombinant IL-1Ra, however, did not offer significant
advantages over anti-TNF blockade in rheumatoid arthritis
patients, and did not show efficacy in patients who were fail-
ing anti-TNF treatment (29, 30). Increased serum level of sol-
uble TNF receptors have been described in SoJIA (31), and it
has been suggested that TNF probably is more important than
IL-1 in the systemic inflammation that characterizes this dis-
ease (32). However, although anti-TNF agents are efficacious
in children within other JIA subgroups (14), most SoJIA pa-
tients do not respond to this therapy. Furthermore, a sub-
group of these patients progresses to an unremitting course
that is unresponsive to any combination of therapies. These
patients also experience significant morbidity from treatment.
Based on our observation that IL-1 production is dysreg-
ulated in SoJIA, we treated nine SoJIA patients who were
failing other therapies with IL-1 blockade and obtained com-
plete disease remission in seven of them. Lack of full response
in two patients may suggest a level of disease heterogeneity
that needs to be addressed further. Two other SoJIA patients
who had prolonged, therapy-resistant disease recently were
reported to respond to IL-1 blockade (33). The unique pat-
tern of cytokine abnormalities and response to biologic ther-
apy that we describe suggests that SoJIA may be classified bet-
ter as an autoinflammatory syndrome, rather than as an
autoimmune disease under the broad spectrum of JIA.
The availability of IL-1Ra may represent a major step to-
ward preventing the development of severe, deforming ar-
thritis and avoiding the use of prolonged corticosteroids and
their devastating side effects in this group of patients. Con-
trolled clinical trials are necessary to delineate clinical re-
sponse, remission duration, and the use of IL-1Ra to substi-
tute eventually for corticosteroids as the first-line treatment
for this disease. The current findings should encourage the
development of other IL-1 antagonists with improved po-
tency and pharmacokinetics.
 
MATERIALS AND METHODS
Patient population
 
PBMCs and sera from 23 SoJIA patients (15 females, 8 males; average age, 7.1
yr) who fulfilled the American College of Rheumatology diagnostic criteria
(34) were collected on repeated occasions. The disease duration, clinical char-
acteristics, and treatment at the time of analysis are summarized in Table I
and  Tables S3–S7 (available at http://www.jem.org/cgi/content/full/jem.
20050473/DC1). Patients were classified as active if they had systemic symp-
toms (fever and/or rash) and/or active arthritis (swollen and/or tender and
limited joints). The control population consisted of 12 children (average age,
14 yr) and 7 adults (average age, 35 yr). The sera from healthy controls were
cultured on repeated occasions with autologous and heterologous PBMCs.
Patients and pediatric controls were recruited at Texas Scottish Rite Hospital
for Children in Dallas. The study was approved by the Institutional Review
Boards (IRBs) of UT Southwestern Medical Center, Texas Scottish Rite
Hospital, and Baylor Health Care System (IRB no. 0199017, 0701–513). In-
formed consent was obtained from parents or legal guardians.
 
PBMC cultures and RNA extraction
 
PBMCs were obtained by Ficoll-Histopaque gradient centrifugation of 20
ml of blood. PBMCs were cultured (10
 
6
 
/ml) in RPMI 1640 supplemented
with 20% autologous or SoJIA patient serum for 6 h. RNA was extracted
using RNAeasy kit (QIAGEN) and assessed using an Agilent 2100 Bioana-
lyzer (Agilent Technologies). Supernatants were frozen at 
 
 
 
80
 
 
 
C. PBMCs
were cultured with RPMI 1640 and 10% FCS with PMA (50 ng/ml)–Ion-
Figure 4. Oral, daily prednisone dose in nine patients treated with 
anakinra at initiation of therapy (time 0) and at last follow-up. 
p-value was obtained by paired Student’s t test. 
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omycin (1 
 
 
 
g/ml) for 24 h. Cells were harvested and the RNA was ex-
tracted as above. Supernatants were frozen at 
 
 
 
80
 
 
 
C.
 
Microarrays and real-time PCR
 
Samples for microarray analysis were processed as described previously (18)
and hybridized to the HG U133A Affymetrix GeneChip array containing
22,283 probe sets (Affymetrix, Inc.) at 45
 
 
 
C for 16 h. GeneChip arrays were
washed, stained, and scanned according to protocols that are described in the
GeneChip Expression Analysis Technical Manual (Affymetrix Inc.). Scanned
GeneChips were inspected visually for abnormalities or irregularities.
 
Data analysis.
 
Intensity values were scaled to 500 using global scaling in
MAS 5.0 and data were exported in MS Excel for import into GeneSpring
software (Silicon Genetics) for gene expression analyses. No “per chip”
normalization was performed because global scaling had been applied in
MAS 5.0. Global scaling adjusts for chip-to-chip variations in hybridization
intensities. Subsequent samples were normalized to pediatric healthy con-
trols and/or to the median of all samples. Statistical comparisons were per-
formed in GeneSpring using parametric (Welch’s approximate 
 
t
 
 test) and
nonparametric (Mann-Whitney U-test) methods. Unsupervised hierarchical
clustering was performed to visualize transcripts that had a control signal of
50 or greater (above the background intensity) and that were identified as
“present” according to MAS 5.0 in 75% of all samples. Statistical compari-
sons were performed in GeneSpring using parametric (Welch’s approximate
 
t
 
 test) and nonparametric (Mann-Whitney U-test) methods. Unsupervised
hierarchical clustering was performed to visualize transcript/sample relation-
ships using standard correlation, Pearson correlation, or Euclidian distance
where indicated.
The GenBank/EMBL/DDBJ accession numbers of the genes pre-
sented in Fig. 1 are (in order of appearance on the figure): M15329;
NM_000576; NM_000877; NM_004633; NM_000600; S69738;
NM_002090; NM_006273; NM_001511; M57731; AK026546;
NM_004591; NM_002993; AI421071; BC005858; NM_001945;
NM_013252; NM_016109; NM_002852; NM_006770; NM_003264;
NM_012072; NM_018643; NM_022842; AI380298; AA576961;
AA156721; H97931; NM_002575; U38321; NM_000963; NM_001912;
X91817; NM_005084; NM_024524; NM_025195; NM_002826;
NM_001995; NM_000361; BF511231; NM_004430; NM_005461;
NM_005306; M74921; BF062629; U73191.
Two-step RT-PCR was performed using Applied Biosystems TaqMan
Assays on Demand probe and primer sets according to the manufacturer’s
instructions and the ABI Prism 7700 Sequence detection System (Applied
Biosystems). The endogenous GAPDH gene and/or 18S RNA were used
for correcting the results with the comparative threshold cycle method for
relative quantification as described by the manufacturer.
 
Multiplex analysis
 
Culture supernatants were analyzed for six cytokines and chemokines using
the FluorikineMAP cytokine assay kit (R&D Systems) as per the manufac-
turer’s protocol.
 
Online supplemental material
 
Table S1 provides a description of the genes that were up-regulated by
SoJIA serum (from Fig. 1, a and b). Table S2 displays the microarray data
corresponding to the 46 probes from Fig. 1 (a and b). For each gene probe,
raw (top) and normalized (bottom) values are provided. Normalization was
done to the value of the corresponding autologous serum cultures (for the
in vitro experiments), and to the median of 12 healthy pediatric controls
(for the patient’s data). Tables S3–S6 show the demographics, clinical symp-
toms, and treatment of the patients whose sera was used in the experiments
that are depicted in Figs. 1, a–d and Fig. 2, a–c, respectively. Tables S7–S15
summarize the core set criteria for visits 0 (time of initiation of Anakinra
treatment and 1 (2-mo follow-up), and the last clinic visit (2–12-mo fol-
low-up). Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20050473/DC1.
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